← News
Jul 21, 2026 Psychedelics
Cybin Renamed Itself Helus Pharma — And Finished Enrolling Its Psilocybin Phase 3 Early
Cybin rebranded to Helus Pharma Inc. (NASDAQ: HELP) in January, moved its US listing to Nasdaq, and renamed its lead compound from CYB003 to HLP003 — same deuterated psilocin, new name. The company just finished enrolling its pivotal Phase 3 trial, APPROACH, ahead of schedule: 223 participants testing HLP003 as an add-on to standard antidepressants for major depressive disorder. Topline data is expected by year-end.
Read at PR Newswire / Helus Pharma